Kancera Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Kancera de winst en omzet met respectievelijk 77.1% en 87.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 160.8% per jaar.

Belangrijke informatie

77.1%

Groei van de winst

160.8%

Groei van de winst per aandeel

Biotechs winstgroei	49.3%
Inkomstengroei	87.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	26 Aug 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

OM:KAN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-15	N/A	N/A	1
12/31/2025	202	169	N/A	169	2
12/31/2024	N/A	-52	N/A	-52	2
6/30/2024	N/A	-53	-51	-51	N/A
3/31/2024	N/A	-60	-51	-51	N/A
12/31/2023	N/A	-65	-56	-56	N/A
9/30/2023	N/A	-60	-52	-52	N/A
6/30/2023	N/A	-61	-58	-58	N/A
3/31/2023	N/A	-58	-57	-57	N/A
12/31/2022	N/A	-52	-48	-48	N/A
9/30/2022	N/A	-51	-53	-53	N/A
6/30/2022	N/A	-52	-50	-50	N/A
3/31/2022	N/A	-49	-44	-44	N/A
12/31/2021	N/A	-46	-44	-44	N/A
9/30/2021	N/A	-45	-41	-41	N/A
6/30/2021	0	-44	-39	-39	N/A
3/31/2021	0	-38	-39	-39	N/A
12/31/2020	0	-40	-39	-39	N/A
9/30/2020	0	-35	-29	-29	N/A
6/30/2020	0	-34	-29	-29	N/A
3/31/2020	0	-40	-36	-36	N/A
12/31/2019	3	-36	-33	-33	N/A
9/30/2019	4	-41	-46	-46	N/A
6/30/2019	3	-44	-53	-53	N/A
3/31/2019	3	-41	-41	-41	N/A
12/31/2018	0	-46	-45	-45	N/A
9/30/2018	0	-46	-50	-50	N/A
6/30/2018	0	-52	-41	-41	N/A
3/31/2018	0	-59	N/A	-54	N/A
12/31/2017	0	-56	N/A	-54	N/A
9/30/2017	0	-51	N/A	-41	N/A
6/30/2017	0	-39	N/A	-40	N/A
3/31/2017	0	-27	N/A	-26	N/A
12/31/2016	0	-22	N/A	-23	N/A
9/30/2016	0	-22	N/A	-22	N/A
6/30/2016	0	-20	N/A	-19	N/A
3/31/2016	0	-20	N/A	-22	N/A
12/31/2015	0	-20	N/A	-21	N/A
9/30/2015	0	-19	N/A	-24	N/A
6/30/2015	0	-18	N/A	-23	N/A
3/31/2015	0	-17	N/A	-21	N/A
12/31/2014	0	-16	N/A	-19	N/A
9/30/2014	2	-13	N/A	-9	N/A
6/30/2014	2	-13	N/A	-9	N/A
3/31/2014	2	-12	N/A	-8	N/A
12/31/2013	2	-7	N/A	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat KAN de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 1.2% ).

Winst versus markt: Er wordt verwacht dat KAN de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat KAN binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van KAN ( 87.7% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( -0.02% per jaar).

Hoge groei-inkomsten: De omzet van KAN ( 87.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van KAN naar verwachting over 3 jaar hoog zal zijn

Kancera Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Recent updates

Kancera AB (Publ) Announces Chief Medical Officer Changes

Kancera AB (Publ) Provides Operational Update Concerning Its Clinical Development Program

New minor risk - Share price stability

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Kancera AB's Fractal Study Results to Be Presented at the ESC 2024 Conference

New major risk - Financial position

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven